Cyclerion Looking To Partner Praliciguat Despite Phase II Fail In Diabetic Nephropathy

 
• By Joseph Haas

The Ironwood spinout thinks its sGC stimulator demonstrated benefit in reducing urine albumin levels in DN patients; notes data improve markedly if one outlier trial site is excluded.

Diagnosis Diabetic Nephropathy photo. Figure of kidney lies next to incription of diagnosis of diabetic nephropathy, ultrasound, stethoscope and laboratory test tubes. Idea of diagnosing of disease - Image
Cyclerion thinks a deeper-pocketed compan should continue development of praliciguat in DN

More from Clinical Trials

More from R&D